SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-21-004064
Filing Date
2021-11-10
Accepted
2021-11-10 16:02:43
Documents
68
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q spro-20210930.htm   iXBRL 10-Q 3591561
2 EX-31.1 spro-ex31_1.htm EX-31.1 12000
3 EX-31.2 spro-ex31_2.htm EX-31.2 12029
4 EX-32 spro-ex32.htm EX-32 10593
  Complete submission text file 0000950170-21-004064.txt   11392418

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT spro-20210930_def.xml EX-101.DEF 290988
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT spro-20210930_cal.xml EX-101.CAL 40555
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT spro-20210930_lab.xml EX-101.LAB 541587
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT spro-20210930_pre.xml EX-101.PRE 433731
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT spro-20210930.xsd EX-101.SCH 75760
10 EXTRACTED XBRL INSTANCE DOCUMENT spro-20210930_htm.xml XML 2038730
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 211396451
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences